Skye Bioscience completed a $17M financing and strategic acquisition of a promising novel technology to expand its pipeline and further position itself as a leader in the arena of endocannabinoid-targeting therapeutics. Listen to Skye’s conference call highlighting this key transaction, the acquisition of Bird Rock Bio and the next steps forward

View the transaction deck here: Transaction overview

Read the transcript: On-demand Call Transcript

Connect with us:

Twitter: @SkyeBioscience
LinkedIn: https://www.linkedin.com/company/skyebioscience
Facebook: https://www.facebook.com/skyebioscience
Newsletter: https://mailchi.mp/21355b06b667

Have questions? Feel free to reach out to ir@skyebioscience.com